Skip to main content
. Author manuscript; available in PMC: 2019 Jan 1.
Published in final edited form as: Exp Neurol. 2017 Apr 6;299(Pt B):270–280. doi: 10.1016/j.expneurol.2017.04.001

Fig. 5.

Fig. 5

iPSCs can be differentiated into NF1-relevant cell types (neuroglial progenitors, Schwann cell progenitors and retinal ganglion cells) for disease modeling and drug discovery. In addition, CRISPR/Cas9 gene editing technology can be utilized to correct germline mutations in retinal ganglion cells for gene therapy in patients with visual impairment.